Human Tetanus Immunoglobulin Market

Human Tetanus Immunoglobulin Market

  • HC-6211
  • 4.8 Rating
  • 330 Pages
  • 14-12-2023
  • 68 Reviews
  • PDF Excel PPT
raksha

Author:

Raksha Sharma

Vineet

Fact-checked by:

Vineet Pandey

Shreyas

Editor:

Shreyas Tandon

Market Outlook:

The Global Human Tetanus Immunoglobulin Market was estimated at USD 615.92 Million in 2022 and is anticipated to reach USD 957.49 Million by 2031, expanding at a CAGR of 5.2% during the forecast period.

Tetanus immunoglobulin (TIG) is recommended for those who have tetanus. TIG only helps to remove unbound tetanus toxin. TIG contains large amounts of antibodies derived from donated human blood. Tetanus Immunoglobulin, used intravenously, is made from human plasma that is the liquid component of blood. Tetanus immunoglobulin is a solution comprising antibodies that provide immediate protection against tetanus. Tetanus Immunoglobulin (TIG) is recommended for tetanus treatment and prophylaxis against tetanus, following injury in patients with insufficient or uncertain tetanus immunization.

Human Tetanus Immunoglobulin Market Outlook

Macro-economic Factors

Global Population

The global population is growing at an alarming rate, putting a major strain on healthcare, increasing susceptibility to  vulnerable groups of people. Overpopulation reduces quality of life and impacts other social and environmental issues. Overpopulation causes malnutrition, pollution, congested living conditions, and a lack of healthcare services, increase the risk of infectious diseases in a community.

Immunization Coverage

According to the World Health Organization (WHO), tetanus is an acute infectious disease caused by spores of the bacterium clostridium tetani. Maternal and neonatal tetanus is still a public health concern in approximately 12 countries, major in Africa and Asia. In 2022, 14.3 million infants did not receive an initial dose of the DTP vaccine, pointing to a lack of access to preventive vaccines (immunization and other health services) lead to increase population of unvaccinated and partially vaccinated people.

Market Dynamics

Major Driver- Increasing Number of Injuries Across the Globe

Increasing incidences of injuries such as chronic wound & infectious injuries, road traffic accidents, sports injuries, and burn injuries are expected to boost the market during the forecast period. For instance, according to a data from World Health Organization (WHO), every year more than 1.19 million people decease as a result of road traffic crashes. These injuries are the primary cause of death for children and young adults aged five to 29 years. The incidence of sports injuries drive the market as well.

For instance, according to a finding, 6.2 million people annually seek hospital treatment in European Union due to sports injuries, and 7% of them, which are 402,000 cases, have to be admitted in hospitals for further treatment.

Major Driver- Occurrence of Tetanus Cases in Developing Countries

Occurrence of tetanus cases in developing nations such as India, Pakistan, Indonesia, Nigeria, Somalia, Kenya, and South Sudan are expected to increase the demand for human tetanus toxoid or vaccines during the forecast period. Moreover, the risk of tetanus infections in immunocompromised patients such as hematologic malignancies, solid-organ transplant, HIV infection, and cancer is rising in these countries. From 1990 to 2019, the incident cases of tetanus decreased by 88% worldwide, from 615,728 to 73,662.

The WHO estimates a growing burden of tetanus among adult men, particularly in countries that do not provide tetanus booster shots. For instance, Sub-Saharan Africa has the high rate of non-neonatal tetanus cases per million population, with men accounting for 71% of hospitalized tetanus patients.

Existing Restraint- High Cost of Tetanus Immunoglobulin Injection

High cost of tetanus immunoglobulin injections is expected to hinder the market during the forecast period. The cost is high, as the manufacturing process is complex, due to the high possibility of contamination. The fluctuating cost of tetanus immunoglobulin injections in different countries is a significant factor in determining their accessibility and affordability for patients.

The high cost of tetanus immunoglobulin injections is anticipated to limit the demand for the product, particularly in low and middle-income countries, where access to healthcare is limited. Thus, patients seek out different treatments or reduce utilization of these injections. Moreover, balancing affordability with quality care is crucial for the sustained market growth.

Emerging Opportunity- Growing Healthcare Infrastructure and Expenditure

Health spending is defined as the final consumption of healthcare goods and services such as current health expenditure. It includes both personal health care such as curative care, rehabilitative care, long-term care, ancillary services, & medical goods and collective services such as prevention & public health services as well as health administration. However, it excludes investment spending.

Health expenditure includes all expenditures for the provision of health services, family planning activities, nutrition activities, and emergency aid designated for health. Global healthcare spending in 2022 was around USD 10,059 Bn. Across the European Union, healthcare spending per capita growth between 2019 and 2022 accelerated to 3.3 %, with a peak in 2021. The top spender across the globe on healthcare is the US with 16.6% spending of its GDP in 2022. It was followed by Germany, which spends 12.7% of its GDP on healthcare, and France, which spends the equivalent of 12.1% of its GDP.

Scope of the Report  

The report on the Global Human Tetanus Immunoglobulin Market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Human Tetanus Immunoglobulin Market– Global Industry Analysis, Size, Share, Growth, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

By Dose (250 IU, and 500 IU), By Age Group (Adults and Children), By End Use (Hospitals, Clinics, and Others), By Sales Channel (Retail Pharmacy, Hospital Pharmacy and Online Pharmacy)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered

Grifols, S.A., CSL Limited, Kedrion Holding S.p.A., GC Biopharma corp., LFB S.A., Incepta Pharmaceuticals Ltd., Bharat Serums and Vaccines Limited, and Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

 

Segmental Outlook

Based on dose, the human tetanus immunoglobulin market is segmented into 250 IU and 500 IU. The 500 IU segment is expected to hold a substantial share of the market during the forecast period, as it provides immediate and short-term protection against the bacteria that cause tetanus or lockjaw. Human tetanus immunoglobulin 500 IU is recommended for treatment of tetanus, following injury in patients whose tetanus immunization is incomplete or uncertain.

Human Tetanus Immunoglobulin Market Dose

Based on age group, the human tetanus immunoglobulin market is segmented into adults and children. The adult’s segment is projected to account for a significant share of the market during the forecast period, due to the rise in prevalence rate of the tetanus infections among adults. For instance, in 2021, 26 Europe/European Economic Area (EU/EEA) countries reported 50 tetanus cases, 10 of which (20%) were classified as confirmed and 40 (80%) as probable.

Human Tetanus Immunoglobulin Market Age Group

Based on end use, the human tetanus immunoglobulin market is segmented into hospitals, clinics, and vaccination centers. The hospital segment is projected to account for a significant share during the forecast period, as hospitals provide a wide range of medical services to patients, including treatment for tetanus infections.

Human Tetanus Immunoglobulin Market End Use

Based on sales channel, the human tetanus immunoglobulin market is segmented into retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy segment is projected to expand at a significant CAGR during the forecast period. The retail pharmacy is expected to register increased sales in the coming years, owing to the growing population and affordability of medicines in retail pharmacies.

Human Tetanus Immunoglobulin Market Sales Channel

Regional Outlook

On the basis of region, the global Human Tetanus Immunoglobulin market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (MEA).

The market in North America accounted for significant market share owing to rising number of injuries by road accidents. For instance, according to a CNBC report, 42,915 people died in motor vehicle traffic crashes in 2021, which is a 10.5% increase from 2020. The presence of robust healthcare infrastructure is anticipated to increase the demand for human tetanus immunoglobulin in North America during the forecast period.

The market in Asia Pacific is projected to expand at a CAGR of 9.5% during the forecast period, owing to the growing awareness regarding immunization programs in developing nations of such as India and Indonesia. The overall success rate of tetanus treatment in China has dramatically improved, but the prevention and control of non-neonatal tetanus is still challenging.

Human Tetanus Immunoglobulin Market Regions

Market Key Developments

  • In December 2022, Kedrion Holding S.p.A. announced the acquisition of the Czech companies UNICAplasma sro and UNICAplasma Morava sro, which operate five plasma collection centers in the Czech Republic.

  • In October 2022, CSL Limited announced the company has entered into a Strategic Option and License Agreement with Arizona-based Translational Sciences for their enhanced thrombus dissolving drug candidate, TS23.

  • In September 2022, Grifols, S.A announced it had signed a pioneering long-term agreement with Canadian Blood Services, Canada’s national blood authority, to greatly increase the country’s self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.

  • In February 2022, Grifols, S.A. announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care, to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis.

Key Benefits for Industry Participants & Stakeholders

  • In-depth Analysis of the Global Human Tetanus Immunoglobulin Market

  • Historical, Current, and Projected Market Size in terms of Value

  • Potential & Niche Segments and Regions Exhibiting Promising Growth Covered

  • Industry Drivers, Restraints, and Opportunities Covered in the Study

  • Recent Industry Trends and Developments

  • Competitive Landscape & Strategies of Key Players

  • Neutral Perspective on Global Human Tetanus Immunoglobulin Market performance

Segments

By Dose

  • 250 IU
  • 500 IU

By Age Group

  • Adults
  • Children

By End Use

  • Hospitals
  • Clinics
  • Others

By Sales Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Key Market Players Profiled in the Report

  • Grifols, S.A.
  • CSL Limited
  • Kedrion Holding S.p.A.
  • GC Biopharma corp.
  • LFB S.A.
  • Incepta Pharmaceuticals Ltd.
  • Bharat Serums and Vaccines Limited
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Competitive Landscape

  • Manufacturers operating in the Global Human Tetanus Immunoglobulin Market include Grifols, S.A., CSL Limited, Kedrion Holding S.p.A., GC Biopharma corp., LFB S.A., Incepta Pharmaceuticals Ltd., Bharat Serums and Vaccines Limited, and Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

  • Market Players are pursuing key strategies such as acquisitions, collaborations, and geographic expansion where a potential opportunity arises for the Human Tetanus Immunoglobulin Market.

    Human Tetanus Immunoglobulin Market Key Players

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4  Human Tetanus Immunoglobulin Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2  Human Tetanus Immunoglobulin Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3  Human Tetanus Immunoglobulin Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the  Human Tetanus Immunoglobulin Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Human Tetanus Immunoglobulin Market Size & Forecast, 2016-2031
      4.5.1  Human Tetanus Immunoglobulin Market Size and Y-o-Y Growth
      4.5.2  Human Tetanus Immunoglobulin Market Absolute $ Opportunity
   4.6 Impact Of Key Regulations

      4.6.1  Standards & Compliances
      4.6.2  Safety
   4.7 Human Tetanus Immunoglobulin Dose Regime
   4.8 Prevalence Rate of Tetanus
   4.9 Pricing Analysis, 2016-2031
   4.10 Safety and clinical efficacy of Human Tetanus Immunoglobulin: Research Overview
Chapter 5 Global Human Tetanus Immunoglobulin Market Analysis and Forecast By Dose
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Dose
      5.1.2 Basis Point Share (BPS) Analysis By Dose
      5.1.3 Absolute $ Opportunity Assessment By Dose
   5.2  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Dose
      5.2.1 250 IU
      5.2.2 500 IU
   5.3 Market Attractiveness Analysis By Dose
Chapter 6 Global Human Tetanus Immunoglobulin Market Analysis and Forecast By Age Group
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Age Group
      6.1.2 Basis Point Share (BPS) Analysis By Age Group
      6.1.3 Absolute $ Opportunity Assessment By Age Group
   6.2  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Age Group
      6.2.1 Adults
      6.2.2 Children
   6.3 Market Attractiveness Analysis By Age Group
Chapter 7 Global Human Tetanus Immunoglobulin Market Analysis and Forecast By End Use
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By End Use
      7.1.2 Basis Point Share (BPS) Analysis By End Use
      7.1.3 Absolute $ Opportunity Assessment By End Use
   7.2  Human Tetanus Immunoglobulin Market Size & Volume Forecast By End Use
      7.2.1 Hospitals
      7.2.2 Clinics
      7.2.3 Others
   7.3 Market Attractiveness Analysis By End Use
Chapter 8 Global Human Tetanus Immunoglobulin Market Analysis and Forecast By Sales Channel
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities By Sales Channel
      8.1.2 Basis Point Share (BPS) Analysis By Sales Channel
      8.1.3 Absolute $ Opportunity Assessment By Sales Channel
   8.2  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Sales Channel
      8.2.1 Retail Pharmacy
      8.2.2 Hospital Pharmacy
      8.2.3 Online Pharmacy
   8.3 Market Attractiveness Analysis By Sales Channel
Chapter 9 Global Human Tetanus Immunoglobulin Market Analysis and Forecast by Region
   9.1 Introduction
      9.1.1 Key Market Trends & Growth Opportunities by Region
      9.1.2 Basis Point Share (BPS) Analysis by Region
      9.1.3 Absolute $ Opportunity Assessment by Region
   9.2  Human Tetanus Immunoglobulin Market Size & Volume Forecast by Region
      9.2.1 North America
      9.2.2 Europe
      9.2.3 Asia Pacific
      9.2.4 Latin America
      9.2.5 Middle East & Africa (MEA)
   9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
   10.1 Introduction
   10.2 Current & Future Impact Analysis
   10.3 Economic Impact Analysis
   10.4 Government Policies
   10.5 Investment Scenario
Chapter 11 North America  Human Tetanus Immunoglobulin Analysis and Forecast
   11.1 Introduction
   11.2 North America  Human Tetanus Immunoglobulin Market Size & Volume Forecast by Country
      11.2.1 U.S.
      11.2.2 Canada
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 North America  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Dose
      11.6.1 250 IU
      11.6.2 500 IU
   11.7 Basis Point Share (BPS) Analysis By Dose
   11.8 Absolute $ Opportunity Assessment By Dose
   11.9 Market Attractiveness Analysis By Dose
   11.10 North America  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Age Group
      11.10.1 Adults
      11.10.2 Children
   11.11 Basis Point Share (BPS) Analysis By Age Group
   11.12 Absolute $ Opportunity Assessment By Age Group
   11.13 Market Attractiveness Analysis By Age Group
   11.14 North America  Human Tetanus Immunoglobulin Market Size & Volume Forecast By End Use
      11.14.1 Hospitals
      11.14.2 Clinics
      11.14.3 Others
   11.15 Basis Point Share (BPS) Analysis By End Use
   11.16 Absolute $ Opportunity Assessment By End Use
   11.17 Market Attractiveness Analysis By End Use
   11.18 North America  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Sales Channel
      11.18.1 Retail Pharmacy
      11.18.2 Hospital Pharmacy
      11.18.3 Online Pharmacy
   11.19 Basis Point Share (BPS) Analysis By Sales Channel
   11.20 Absolute $ Opportunity Assessment By Sales Channel
   11.21 Market Attractiveness Analysis By Sales Channel
Chapter 12 Europe  Human Tetanus Immunoglobulin Analysis and Forecast
   12.1 Introduction
   12.2 Europe  Human Tetanus Immunoglobulin Market Size & Volume Forecast by Country
      12.2.1 Germany

      12.2.2 France
      12.2.3 Italy
      12.2.4 U.K.

      12.2.5 Spain
      12.2.6 Russia
      12.2.7 Rest of Europe
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Europe  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Dose
      12.6.1 250 IU
      12.6.2 500 IU
   12.7 Basis Point Share (BPS) Analysis By Dose
   12.8 Absolute $ Opportunity Assessment By Dose
   12.9 Market Attractiveness Analysis By Dose
   12.10 Europe  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Age Group
      12.10.1 Adults
      12.10.2 Children
   12.11 Basis Point Share (BPS) Analysis By Age Group
   12.12 Absolute $ Opportunity Assessment By Age Group
   12.13 Market Attractiveness Analysis By Age Group
   12.14 Europe  Human Tetanus Immunoglobulin Market Size & Volume Forecast By End Use
      12.14.1 Hospitals
      12.14.2 Clinics
      12.14.3 Others
   12.15 Basis Point Share (BPS) Analysis By End Use
   12.16 Absolute $ Opportunity Assessment By End Use
   12.17 Market Attractiveness Analysis By End Use
   12.18 Europe  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Sales Channel
      12.18.1 Retail Pharmacy
      12.18.2 Hospital Pharmacy
      12.18.3 Online Pharmacy
   12.19 Basis Point Share (BPS) Analysis By Sales Channel
   12.20 Absolute $ Opportunity Assessment By Sales Channel
   12.21 Market Attractiveness Analysis By Sales Channel
Chapter 13 Asia Pacific  Human Tetanus Immunoglobulin Analysis and Forecast
   13.1 Introduction
   13.2 Asia Pacific  Human Tetanus Immunoglobulin Market Size & Volume Forecast by Country
      13.2.1 China
      13.2.2 Japan
      13.2.3 South Korea
      13.2.4 India
      13.2.5 Australia
      13.2.6 South East Asia (SEA)
      13.2.7 Rest of Asia Pacific (APAC)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Asia Pacific  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Dose
      13.6.1 250 IU
      13.6.2 500 IU
   13.7 Basis Point Share (BPS) Analysis By Dose
   13.8 Absolute $ Opportunity Assessment By Dose
   13.9 Market Attractiveness Analysis By Dose
   13.10 Asia Pacific  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Age Group
      13.10.1 Adults
      13.10.2 Children
   13.11 Basis Point Share (BPS) Analysis By Age Group
   13.12 Absolute $ Opportunity Assessment By Age Group
   13.13 Market Attractiveness Analysis By Age Group
   13.14 Asia Pacific  Human Tetanus Immunoglobulin Market Size & Volume Forecast By End Use
      13.14.1 Hospitals
      13.14.2 Clinics
      13.14.3 Others
   13.15 Basis Point Share (BPS) Analysis By End Use
   13.16 Absolute $ Opportunity Assessment By End Use
   13.17 Market Attractiveness Analysis By End Use
   13.18 Asia Pacific  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Sales Channel
      13.18.1 Retail Pharmacy
      13.18.2 Hospital Pharmacy
      13.18.3 Online Pharmacy
   13.19 Basis Point Share (BPS) Analysis By Sales Channel
   13.20 Absolute $ Opportunity Assessment By Sales Channel
   13.21 Market Attractiveness Analysis By Sales Channel
Chapter 14 Latin America  Human Tetanus Immunoglobulin Analysis and Forecast
   14.1 Introduction
   14.2 Latin America  Human Tetanus Immunoglobulin Market Size & Volume Forecast by Country
      14.2.1 Brazil
      14.2.2 Mexico
      14.2.3 Rest of Latin America (LATAM)
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Latin America  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Dose
      14.6.1 250 IU
      14.6.2 500 IU
   14.7 Basis Point Share (BPS) Analysis By Dose
   14.8 Absolute $ Opportunity Assessment By Dose
   14.9 Market Attractiveness Analysis By Dose
   14.10 Latin America  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Age Group
      14.10.1 Adults
      14.10.2 Children
   14.11 Basis Point Share (BPS) Analysis By Age Group
   14.12 Absolute $ Opportunity Assessment By Age Group
   14.13 Market Attractiveness Analysis By Age Group
   14.14 Latin America  Human Tetanus Immunoglobulin Market Size & Volume Forecast By End Use
      14.14.1 Hospitals
      14.14.2 Clinics
      14.14.3 Others
   14.15 Basis Point Share (BPS) Analysis By End Use
   14.16 Absolute $ Opportunity Assessment By End Use
   14.17 Market Attractiveness Analysis By End Use
   14.18 Latin America  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Sales Channel
      14.18.1 Retail Pharmacy
      14.18.2 Hospital Pharmacy
      14.18.3 Online Pharmacy
   14.19 Basis Point Share (BPS) Analysis By Sales Channel
   14.20 Absolute $ Opportunity Assessment By Sales Channel
   14.21 Market Attractiveness Analysis By Sales Channel

Chapter 15 Middle East & Africa (MEA)  Human Tetanus Immunoglobulin Analysis and Forecast
   15.1 Introduction
   15.2 Middle East & Africa (MEA)  Human Tetanus Immunoglobulin Market Size & Volume Forecast by Country
      15.2.1 Saudi Arabia
      15.2.2 South Africa
      15.2.3 UAE
      15.2.4 Rest of Middle East & Africa (MEA)
   15.3 Basis Point Share (BPS) Analysis by Country
   15.4 Absolute $ Opportunity Assessment by Country
   15.5 Market Attractiveness Analysis by Country
   15.6 Middle East & Africa (MEA)  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Dose
      15.6.1 250 IU
      15.6.2 500 IU
   15.7 Basis Point Share (BPS) Analysis By Dose
   15.8 Absolute $ Opportunity Assessment By Dose
   15.9 Market Attractiveness Analysis By Dose
   15.10 Middle East & Africa (MEA)  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Age Group
      15.10.1 Adults
      15.10.2 Children
   15.11 Basis Point Share (BPS) Analysis By Age Group
   15.12 Absolute $ Opportunity Assessment By Age Group
   15.13 Market Attractiveness Analysis By Age Group
   15.14 Middle East & Africa (MEA)  Human Tetanus Immunoglobulin Market Size & Volume Forecast By End Use
      15.14.1 Hospitals
      15.14.2 Clinics
      15.14.3 Others
   15.15 Basis Point Share (BPS) Analysis By End Use
   15.16 Absolute $ Opportunity Assessment By End Use
   15.17 Market Attractiveness Analysis By End Use
   15.18 Middle East & Africa (MEA)  Human Tetanus Immunoglobulin Market Size & Volume Forecast By Sales Channel
      15.18.1 Retail Pharmacy
      15.18.2 Hospital Pharmacy
      15.18.3 Online Pharmacy
   15.19 Basis Point Share (BPS) Analysis By Sales Channel
   15.20 Absolute $ Opportunity Assessment By Sales Channel
   15.21 Market Attractiveness Analysis By Sales Channel
Chapter 16 Competition Landscape
   16.1  Human Tetanus Immunoglobulin Market: Competitive Dashboard
   16.2 Global Human Tetanus Immunoglobulin Market: Market Share Analysis, 2022
   16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
      16.3.1 Grifols, S.A.
      16.3.2 CSL Limited
      16.3.3 Kedrion Holding S.p.A
      16.3.4 GC Biopharma corp.
      16.3.5 LFB S.A.
      16.3.6 Incepta Pharmaceuticals Ltd.
      16.3.7 Bharat Serums and Vaccines Limited
      16.3.8 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Purchase Premium Report

FAQ Section

Some frequently asked quetions about this report!

The base year considered for the Global Human Tetanus Immunoglobulin Market report is 2022. The complete analysis period is 2021 to 2031, wherein, 2016, and 2021 are the historic years, and the forecast is provided from 2023 to 2031.

In addition to market size (in US$ Million) Company Market Share (in % for the base year 2022), Global Human Tetanus Immunoglobulin Market: Impact of Key Regulations, Human Tetanus Immunoglobulin Dose Regime, Prevalence Rate of Tetanus, Pricing Analysis, 2016-2031, and Safety and clinical efficacy of Human Tetanus Immunoglobulin: Research Overview.

The outbreak of coronavirus disease in 2019 (COVID-19) hampered global economy, created global interdependence, and challenged governments of many nations. The long-term effects of the pandemic are expected to hamper various industries during the forecast period, especially across Eastern Europe, the European Union, Eastern & Central Asia, and the US.

Major manufacturers include Grifols, S.A., CSL Limited, Kedrion Holding S.p.A., GC Biopharma corp., LFB S.A., Incepta Pharmaceuticals Ltd., Bharat Serums and Vaccines Limited, and Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Global Population, Immunization Coverage, Government Healthcare Policies, and Growth in Healthcare Industry are expected to act as macroeconomic factors for the market.

Adults and Children are the end-user of Human Tetanus Immunoglobulin.

According to this Growth Market Reports report, the Human Tetanus Immunoglobulin Market is likely to register a CAGR of 5.2% during the forecast period 2022-2031, with an anticipated valuation of USD 957.49 Million by the end of 2031.

Increasing Number of Injuries Across the Globe, Occurrence of Tetanus Cases in Developing Countries, Growing Awareness Regarding Immunization Programs, and Presence of Robust Healthcare Infrastructure and Accessibility of Tetanus Immunoglobulin are the factors driving the growth of the Human Tetanus Immunoglobulin Market.

Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.

Additional company profiles can be provided on request. For a discussion related to the above findings, click Speak to Analyst